Stem Cell Clinic

3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along…

VANCOUVER, BC, Aug. 17, 2021 /PRNewswire/ -- The global 3D bioprinting market size is expected to reach USD 2,687.8 Million in 2027 at a CAGR of 20.7% during the forecast period, according to the recent report by Emergen Research. Rapid technological advancements in 3D bioprinters, increasing investment to accelerate research and development activities of bioprinters, and rising use of 3D bioprinters to develop biomaterials for drug research and regeneration of joints and ligaments are key factors expected to drive market revenue growth over the forecast period. In addition, numerous advantages of 3D bioprinting in organ reconstruction to treat various end-stage disorders is another key factor contributing to the revenue growth of the market.

Emergen_Research_Logo

3D bioprinting leverages techniques similar to additive manufacturing to mix up growth factors, cells, and biomaterials to create biomedical parts that can mimic natural tissue attributes. 3D bioprinting leverages layer-by-layer technique to add materials called as bioinks to create tissue-like structures that can be used in medical and tissue engineering procedures. Recent advancements in the technique has expanded its scope in drug design and development by creating target tissues and cells for drug research and testing. In addition, 3D bioprinters can be used to reconstruct tissues from any body part and this has further increased its applications for treating various severe and chronic disorders. Significant progress in tissue engineering and production of biomaterials have contributed considerably to the 3D bioprinting market growth.

Download FREE Sample Brochure (Customized Sample PDF File delivered as per your specific requirement)@ https://www.emergenresearch.com/request-sample/133

3D bioprinters have been extensively used in vaccine research during the COVID-19 pandemic. Bioprinting is widely being used in the development of regenerative medicines, stem cell therapies, drug research and therapies, and tissue and organ reconstruction. Increasing application of 3D bioprinting in cosmetic and pharmaceutical sector is also a key factor contributing to the revenue growth of the market going ahead. However, lack of skilled professionals and technical knowledge, high costs of 3D bioprinting, and limited access to advanced technologies in developing and underdeveloped countries are some key factors expected to restrain market growth to a significant extent over the forecast period.

Story continues

Some Key Highlights in the Report:

Inkjet-based printing segment is expected to account for largest revenue share over the forecast period owing to increasing adoption of ink-jet-based printing in healthcare industry for biofabrication of tissues and cells and in drug delivery approaches owing to its cost-effectiveness, higher reliability, and increased efficiency.

Living cells segmented accounted for a significantly large revenue share in the global market in 2019 and is expected to register considerable revenue growth going ahead owing to increasing use of living cells in stem cell research and regenerative medicine.

Research application dominated other segments in terms of revenue in 2019 and is expected to register robust revenue CAGR over the forecast period owing to increasing investment to accelerate R&D activities, rapid progress in stem cell research, and growing demand for regenerative medicine owing to increasing incidence of chronic diseases.

North America market revenue is expected to expand significantly over the forecast period owing to establishment of state-of-the-art healthcare facilities, increasing R&D activities in stem cell and regenerative medicine, rising investment by public and private organizations, and presence of key players in the region.

Asia Pacific is expected to register robust revenue CAGR over the forecast period owing to increasing demand for tissue and organ transplants, growing preference for cosmetic surgeries, and increasing investment to boost drug research and development.

Key companies in the market include Allevi Inc., Organovo Holdings, Inc., CELLINK, Aspect Biosystems Ltd., Cyfuse Biomedical K.K., EnvisionTEC GmbH, TeVido BioDevices, Poietis, Digilab, Inc., and Nano3D Biosciences, Inc, among others.

In July 2021, T&R Biofab, which is a Korean 3D printer manufacturer, announced successful fabrication of liver tissues and translation into an animal test subject for the first time ever in a groundbreaking research step. Leveraging the firm's 3DX bioprinter, researchers have been able to develop spherical microtissues into structures that can replicate the "lobules" found in human liver.

Buy your Exclusive copy [Make Payment ]@ https://www.emergenresearch.com/select-license/133

For the purpose of this report, Emergen Research has segmented the global 3D bioprinting market on the basis of technology, material, application, and region:

Technology Outlook (Revenue, USD Million; 2017-2027)

Laser-based

Inkjet-based

Syringe-based

Magnetic Levitation

Others

Material Outlook (Revenue, USD Million; 2017-2027)

Hydrogels

Living Cells

Extracellular Matrices

Others

Application Outlook (Revenue, USD Million; 2017-2027)

Clinical Application

Research Application

Have a look at Report Description and Table of Contents of Market Research Report@ https://www.emergenresearch.com/industry-report/3d-bioprinting-market

Regional Outlook (Revenue, USD Million; 2017-2027)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Explore more reports offered by Emergen Research:

The Global Oncology Informatics Market size was valued at USD 4.62 Billion in 2019 and is anticipated to reach USD 8.01 Billion by 2027 at a CAGR of 7.1%. An increase in the awareness of the different types of treatment options for oncology will drive the demand for the oncology informatics market. The major driving factor is the rise in the prevalence of cancer and heavy investment by the government institutes and research organizations.

The Global Nerve Repair and Regeneration Market size was valued at USD 6.05 Billion in 2019 and is forecasted to reach USD 11.62 Billion by 2027 at a CAGR of 9.0%. The market is mainly driven by the rising geriatric population and the increasing prevalence of nerve injuries. The high incidence of neurological disorders among the growing population is expected to drive the Nerve Repair and Regeneration Market growth.

The Global Spinal Fusion Devices Market size was valued at USD 6.88 Billion in 2019 and is forecasted to reach USD 8.90 Billion by 2027 at a CAGR of 3.5%. The market is mainly driven by the increasing aging population and their growing need for spine care. Advancements in surgical technology is a key contributing factor behind the increasing demand for spinal fusion devices over the forecast period.

The Global Interventional Oncology Devices Market size was valued at USD 1.92 Billion in 2019 and is expected to reach USD 3.11 Billion by 2027 at a CAGR of 6.6%. The global Interventional Oncology Devices market is forecasted to expand exponentially owing to the rising preference for minimally invasive surgical procedures. The increasing government initiatives to support Interventional Oncology is anticipated to further propel the market growth over the forecasted timeframe.

The global spinal implants and surgery devices market size was valued at USD 10.22 Billion in 2019 and is forecasted to reach USD 14.70 Billion by 2027 at a CAGR of 4.6%. The spinal implants and surgery devices market is observing high demand owing to factors including the rising occurrence of spinal disorders, a rise in the elderly population, growing inclination for less invasive surgery, and growing research activities for developing technologically updated in spinal devices.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:Eric Lee Corporate Sales Specialist Emergen Research | Web: http://www.emergenresearch.com Direct Line: +1 (604) 757-9756 E-mail: sales@emergenresearch.com Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.emergenresearch.com/press-release/global-3d-bioprinting-market

Cision

View original content:https://www.prnewswire.com/news-releases/3d-bioprinting-market-size-to-reach-usd-2-687-8-million-in-2027--increasing-use-of-3d-bioprinters-in-medical-procedures-training-and-testing-along-with-organ-engineering-and-regenerative-medicine-are-some-key-factors-driving-ind-301356592.html

SOURCE Emergen Research

More here:
3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along...

Acute Myeloid Leukemia Treatment: What You Need to Know – Healthline

The umbrella term of leukemia encompasses several distinct types of leukemia, including acute myeloid leukemia (AML).

In 2021, its estimated that over 20,000 new cases of AML will be diagnosed, according to the National Cancer Institute (NCI). Since treatment varies depending on the specific kind of leukemia present, an accurate diagnosis is crucial.

There are a variety of treatments for AML. Your doctor will explain them and help choose a treatment plan based on the type of cancer you have and your individual situation.

Read on to learn more about the various treatment options for AML.

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It affects white blood cells (WBCs), making them abnormal. In some forms of AML, they may also multiply very quickly.

Other names for AML include:

Read this for more information about AML.

Once the diagnosis is confirmed, your healthcare team will develop a plan to treat AML. Depending on the specific type and stage of AML, you may receive one or more of these treatments:

Chemotherapy is the main form of treatment for AML. Its divided into two phases:

Since AML can progress quickly, treatment is usually started as soon as possible after diagnosis. Other treatments may be used as well.

Chemotherapy, also called chemo, is the use of anti-cancer drugs to treat cancer. This is the main treatment for AML.

These drugs can be injected into a vein or under the skin, allowing the chemotherapy to travel through the bloodstream to attack cancer cells throughout the body. If leukemia has been found in the brain or spinal cord, chemo medication may be injected into the cerebrospinal fluid (CSF).

Chemo medications most often used to treat AML include:

Other chemo medications may include:

Side effects of chemotherapy can vary depending on the drug, dosage, and duration. They can include:

While chemotherapy is the main treatment for AML, for a subtype of AML called acute promyelocytic leukemia (APL), other non-chemotherapy drugs are more effective.

APL is caused by a specific gene mutation that affects WBCs. Some medications work better than chemo to help those cells develop normally. Two of these medications are:

ATRA can be given with chemotherapy or with ATO for the initial treatment of APL. Both drugs can also be given during consolidation.

Side effects of ATRA include:

Side effects of ATO can include:

Radiation therapy uses high-energy radiation to kill cancer cells. While its not the main treatment for those with AML, it can be used in treating AML. In AML, the radiation used is external beam radiation, which is similar to an X-ray.

Radiation can be used in AML to treat:

Side effects of radiation can include:

Surgery is rarely used in AML treatment. Leukemia cells are spread through the bone marrow and blood, making the condition impossible to improve with surgery. On rare occasions, a tumor or mass related to leukemia may form that may be treated with surgery.

Prior to chemotherapy, a small surgery to place a central venous catheter (CVC) or a central line, is often done. During this procedure, a small flexible tube is placed into a large vein in the chest. The end of it is either right under the skin or sticks out in the chest or upper arm.

Having a central line installed allows the treatment team to give intravenous medication and chemotherapy through the CVC, and to draw blood from it, reducing the number of needle sticks an individual has to have.

While chemotherapy is the main treatment for AML, it has its limits. Since high doses of these medications are toxic, the dosage must be limited. A stem cell transplant allows for higher doses of chemotherapy medications.

In a stem cell transplant, very high doses of chemotherapy medications, sometimes combined with radiation, are given. All of the individuals original bone marrow is destroyed on purpose.

Once this stage of therapy is over, blood-forming stem cells are given. These stem cells will grow, rebuilding the bone marrow. Healthy, cancer-free stem cells replace the destroyed bone marrow.

Read this article for more information about a stem cell transplant.

Targeted therapy drugs are medications that target only certain parts of cancer cells. They can be very effective for some people with AML. Most targeted therapy drugs are taken orally, except for gemtuzumab ozogamicin (Mylotarg), which is given as an intravenous infusion.

Talk with your treatment team about the potential side effects of each drug and what you should watch for when taking it. Some targeted therapy medications include:

One type of targeted therapy medication called FLT3 inhibitors targets the FLT3 gene. In some people with AML, a mutation in the FLT3 gene causes the creation of a protein, also called FLT3, that enables cancer cells to grow. Drugs in this category include:

Side effects of these drugs may include:

In some people with AML, there is a mutation in the IDH2 gene. These mutations stop bone marrow cells from maturing in a normal way. Medications called IDH inhibitors block IDH proteins produced by these mutated genes, allowing these bone marrow cells to grow normally and remain healthy.

Drugs in this category include:

Side effects can include:

AML cells contain a protein called CD33. A medication called gemtuzumab ozogamicin (Mylotarg) attaches to this CD33 protein and helps deliver chemotherapy medications directly to cancer cells so that these drugs are more effective.

Common side effects include:

There are less common but serious side effects like:

Venetoclax (Venclexta) is a BCL-2 inhibitor. This drug targets BCL-2, which is a protein that helps cancer cells live longer. The drug stops the BCL-2 protein from helping cancer cells survive so that these cancer cells die sooner. This medication can be used along with other chemotherapy drugs.

Side effects include:

AML can cause cellular mutations that prevent cells like bone marrow cells from developing and functioning normally. These mutations may affect the pathway cells use to send necessary signals. This pathway is called hedgehog. For some people with AML, especially those over age 75, strong chemo medications may be so harmful that chemo is not an option. For these individuals, a medication called, Glasdegib (Daurismo), may help them live longer. This medication helps stop the mutations and allows bone marrow cells to function normally.

Side effects of this medication may include:

Refractory AML happens when an individual is not in remission even after one to two cycles of induction chemotherapy, which means they have a blast count of 5 percent or more. Ten to 40 percent of people with AML have refractory AML.

If treatment isnt successful with one course of chemo, another one may be done. If a person is still not in remission after the second course of chemo, they may be given other medications or an increased dose of their current chemotherapy medications.

Other treatment options include stem cell transplant or a clinical trial of new therapies.

When an individual has no evidence of disease after treatment, its called remission or complete remission. Remission means these three criteria are met:

If there is no evidence at all of leukemia cells in the bone marrow, using highly sensitive tests, its called complete molecular remission. Minimal residual disease (MRD) occurs when, after treatment, leukemia cells cannot be seen in the bone marrow with standard tests but more sensitive tests like PCR tests do find leukemia cells.

Even after an individual has entered remission, they will likely need follow-up care and will need to be monitored by their doctor and healthcare team. This may mean additional tests, more frequent physical exams, and other care.

Although chemotherapy is the main treatment for AML, there are a variety of treatment options, depending on the AML subtype or whether you have a specific mutation. Treatment also depends on your response to initial treatment and whether or not remission is sustained.

Your treatment team will explain all of your treatment options and help you choose the treatment plan that is best for you and your individual situation.

View post:
Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline

Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 – The Market Writeuo – The Market Writeuo

New Jersey, United States,-Verified Market Research recently released a new report titled Stem Cell Alopecia Treatment MarketSize Report, Growth and Forecast 2021-2028, Breakdown Data by Company, Key Regions, Types and Applications. The report has been compiled using primary and secondary research methodology that will provide a precise and precise understanding of the Stem Cell Alopecia Treatment market. Analysts used a top-down and bottom-up approach to assess the segments and properly assess their impact on the Stem Cell Alopecia Treatment market. The report offers a market overview which briefly describes the market situation and major segments. It also mentions the best players represented in the Stem Cell Alopecia Treatment market.

The 2021 report offers an in-depth analysis of each sector of this Stem Cell Alopecia Treatment industry. Fill in historical Stem Cell Alopecia Treatment data according to customer requirements. It offers Stem Cell Alopecia Treatment market research globally and locally. The detailed segment and manufacturer information of Stem Cell Alopecia Treatment helps guide future benefits and make important decisions for the growth of Stem Cell Alopecia Treatment.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketresearch.com/download-sample/?rid=15102

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute.

Stem Cell Alopecia Treatment Market Segmentation

Stem Cell Alopecia Treatment Market, By Indication

Male Pattern Baldness Female Pattern Baldness Others

In the next chapters, the research report reveals the development of the Stem Cell Alopecia Treatment market segments. Analysts have segmented the market on the basis of product, application, end-users, and geography. Each segment of the Stem Cell Alopecia Treatment market has been studied with in-depth insight. Analysts have evaluated the changing nature of the market segments, growing investments in manufacturing activities, and product innovation that are likely to impact them. In terms of geography, the report studies the changing political environment, social upliftment, and other government initiatives that are expected to contribute to the regional markets.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102

Stem Cell Alopecia Treatment Market Report Scope

Geographic Segment Covered in the Report:

North America (USA and Canada) Europe (UK, Germany, France and the rest of Europe) Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region) Latin America (Brazil, Mexico, and the rest of Latin America) Middle East and Africa (GCC and rest of the Middle East and Africa)

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/

Visualize Stem Cell Alopecia Treatment Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Stem Cell Alopecia Treatment Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

View original post here:
Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 - The Market Writeuo - The Market Writeuo

Some Residents Should Consider Third COVID-19 Vaccine Dose – Wyoming Department of Health

August 17, 2021

A third vaccine dose is now being recommended for a limited group of Wyoming residents with certain medical conditions, according to the Wyoming Department of Health (WDH).

Dr. Alexia Harrist, state health officer and state epidemiologist with WDH, said the Centers for Disease Control and Prevention (CDC) recommends people with moderately to severely compromised immune systems should receive an additional dose of Pfizer or Moderna COVID-19 vaccines.

National experts are seeing that people who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness, Harrist said. An additional dose of the Pfizer or Moderna vaccines can help these people make sure they have enough protection against COVID-19.

Harrist said those who should consider an additional vaccine dose at this time include people who have:

Added doses have NOT yet been authorized or recommended and are not available at this time for people without compromised immune systems or who may have received the one-dose Johnson and Johnson vaccine.

The additional dose for people with compromised immune systems should be administered at least 28 days after the original vaccination series is completed. Residents with questions on whether they should consider the additional dose are encouraged to discuss the recommendation with their regular medical professional.

More important details about the current third-dose recommendation from the CDC can be found at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.

The authorized vaccines each continue to offer solid protection from infection for Wyoming residents, including against the Delta variant, Harrist said.

An updated WDH review of more than 7,000 lab-confirmed and probable cases identified among Wyoming residents age 18 and older between May 1 and August 10 shows just over 95 percent of the individuals did not report being fully vaccinated against COVID-19. During the same period, of the nearly 350 persons infected by COVID-19 who were hospitalized at the time they were interviewed by public health representatives, just under 95 percent did not report being fully vaccinated against COVID-19.

Harrist continues to encourage residents to seek out free, safe and effective COVID-19 vaccines, which remain readily available across Wyoming. As always, we will continue sharing information about future vaccine-related recommendations, she said.

Convenient ways to find where to get COVID-19 vaccines include:

A person is considered fully vaccinated two weeks after two doses of either the Pfizer or Moderna vaccine or two weeks after one dose of the Johnson and Johnson (Janssen) vaccine.

More information from WDH about vaccination in Wyoming can be found at https://health.wyo.gov/publichealth/immunization/wyoming-covid-19-vaccine-information/.

Read the rest here:
Some Residents Should Consider Third COVID-19 Vaccine Dose - Wyoming Department of Health

Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL – Targeted Oncology

The open-label, randomized BRUIN trial will compare LOXO-305 to investigators choice of either ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa). Approximately 500 patients will be enrolled in the study.

"MCL patients who have been treated with a covalent BTK inhibitor have very few therapeutic options, and outcomes are extremely poor. LOXO-305 has demonstrated a promising efficacy profile in these patients, a setting where we urgently need new therapies," said Michael Wang, MD, Puddin Clarke Endowed professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, in a press release.

The primary end point of BRUIN is progression-free survival (PFS), and the secondary end points include event-free survival, time to treatment failure, time to worsening of MCL-related symptoms, comparative tolerability, overall response rate (ORR), duration of response, and overall survival.

A confirmed diagnosis of MCL is required for inclusion in the study as well as being previously treated with at least 1 prior line of systemic therapy for MCL, having measurable disease per Lugano criteria, having an ECOG performance status of 0 to 2, and having adequate laboratory values at baseline.

In the case of prior treatment with an FDA-approved or investigational BTK inhibitor, patients are ineligible to enroll in the study. According to the criteria, patients are also excluded if they have a history of bleeding diathesis, stroke, or intracranial hemorrhage within 6 months of randomization, and prior allogeneic stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T-cell therapy within 60 days of randomization. In addition, patients with significant cardiovascular disease, and other comorbidities that may interfere with study treatment are not eligible to enroll.

Treatment with LOXO-305 has already shown promise for the treatment of 323 patients with previously treated B-cell malignancies. In the phase 1/2 BRUIN study, the use of the agent was investigated in patients with MCL, chronic lymphocytic leukemia/small lymphocytic leukemia, Waldenstroms macroglobulinemia (WM), and other B-cell malignancies. The patients were pretreated with a BTK inhibitor (95%), anti-CD20 antibody (98%), chemotherapy (92%), lenalidomide (Revlimid; 20%), autologous transplant (25%), CAR T-cell therapy (5%), and ASCT.3

According to data presented during the 2020 American Society of Hematology Annual Meeting, the ORR observed with LOXO-305 in 59 efficacy-evaluable patients from the MCL cohort was 52% (95% CI, 38%-65%), which included 14 complete and 15 partial responses. The median time to the first response in these patients was 1.8 months.

In the WM cohort of 19 efficacy-evaluable patients, the ORR observed was 68% (95% CI, 44%-87)%, which notably was similar in patients who were previously treated with a BTK inhibitor (69%; 95% CI, 39%-91%). Further, 4 out of 8 patients with follicular lymphoma had a response to LOXO-305, in addition to 75% of the evaluable Richter's transformation cohort, and 8 out of 35 patients with other B-cell malignancies, including diffuse large B-cell lymphoma and marginal zone lymphoma.

The most commonly reported adverse events (AEs) with LOXO-305 in the phase 1/2 BRUIN study were fatigue (20%), diarrhea (17%), and contusion (13%). Eight percent of patients had dose interruptions due to AEs, while 2.2% had dose reduction, and 1.5% permanently discontinued treatment with LOXO-305.

LOXO-305 was designed to overcome some of the limitations seen with current BTK therapies and we believe the promising efficacy and tolerability data demonstrate its potential to be an important new treatment option for MCL patients, said David Hyman, MD, chief medical officer of Loxo Oncology at Lilly, in a press release.

References:

1. Mato AR, Pagel JM, Coombs CC, et al. 542LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: results from the phase 1/2 bruin study. . Presented at: 2020 ASH Annual Meeting and Exposition. December 4-8, 2020; Virtual. Abstract 542.

2. Study of BTK inhibitor LOXO-305 versus approved BTK inhibitor drugs in patients withmantle cell lymphoma(MCL) (BRUIN-MCL-321). Clnicaltrials.gov. Accessed August 17, 2021. https://bit.ly/3CXTgu4

3. Loxo Oncology at Lilly announces updated data from the phase 1/2 BRUIN Clinical Trial for LOXO-305 in mantle cell lymphoma and non-Hodgkin lymphomas at the American Society of Hematology (ASH) Annual Meeting. News release. Loxo Oncology at Lilly. December 5, 2020. accessed August 17, 2021. https://prn.to/37QNw7a

Read more:
Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL - Targeted Oncology